Suchitra Sundaram

Lymphoma/CLL physician at Mount Sinai Icahn School of Medicine, NYC. Former lymphoma doc @RoswellPark.👩‍🎓: @ClevelandClinic @CWRU

[Suchitra Sundaram @SSundaramMD]

@sridevirajeeve @ABIMcert @SinaiHemeOnc @TischCancer @IcahnMountSinai @MountSinaiNYC Congratulations Sridevi ! So proud of you !👏

[Suchitra Sundaram @SSundaramMD]

Excellent Junior Faculty career development session on now at #ASH23 Dr. Oyebimpe Adesina and Dr. Cassandra Josephson sharing their journey on securing and staying funded as junior faculty. Great tips and many take-aways! “Persistence is key” #lymsm

[Suchitra Sundaram @SSundaramMD]

Useful data by Dr.Lacoboni: Prior Benda exposure did NOT impact CRS,toxicities, survival w/BsAb therapy in DLBCL&FL. More pts w/shorter washout b4 BsAb needed to explore the impact of more recent Benda exposure on outcomes,(small# DLBCL pts with Benda use within 6m had lower PFS)

[Suchitra Sundaram @SSundaramMD]

Another ctDNA study suggesting greater predictive value over PET.
@RoschewskiMD EOT response post 1L in DLBCL, Landmark comparison of EOT PET vs ctDNA.
Undetectable ctDNA by PhasED-sea at EOT predicts a very low likelihood of progression potentially sparing more biopsies/imaging

[Suchitra Sundaram @SSundaramMD]

Sworder et al
MRD detection in DLBCL using PhasED-Seq
Ct-DNA-MRD predicts outcomes when discordant with PET: Outcomes for CT-DNA+, PET - worse than CTDNA-PET+. Need to overcomes barriers for its use to treat & consolidate in RW practice #ASH23

[Suchitra Sundaram @SSundaramMD]

Simplify geriatric assessments! Easy to administer “Timed up and go” as an objective measure of frailty and predictor of severe therapy related toxicity in DLBCL. Outstanding work by ⁦⁦@PallawiTorkaMD⁩ #lymsm #ASH23

[Suchitra Sundaram @SSundaramMD]

Shout out to my fellow LSRMP colleague @ArushiKhurana4 analysis of BCL6-R outcomes in the LEO consortium
BCL-6 DHL outcomes are more comparable to DLBCL NOS than BCL 2 R #ASH23

[Pallawi Torka @PallawiTorkaMD]

I’m tired of my job!
Work is not fun anymore!

‘Should I stay or should I go?’

Join @UDurani @MayoClinic and me @RoswellPark as we chat about
👉 pros/cons
👉strategies for success

Session: Junior Faculty Career Development #ASH22
Time: 4.30-5.45pm Monday (we start at 5 pm)

[Suchitra Sundaram @SSundaramMD]

@PallawiTorkaMD @PaolaGhione_MD Missing hanging out with you too !

[Suchitra Sundaram @SSundaramMD]

@PallawiTorkaMD @NEJM @RoswellPark Congratulations !!

[Pallawi Torka @PallawiTorkaMD]

Ofatumumab- HyperCVAD in MCL

This paper has been in making for many years and am proud to announce that its finally out in #CancerJournal.

O-HyperCVAD induced 96% MRD negativity by flow post induction
but PFS and OS only 46 mo and 56 mo still

https://t.co/0c9duyjNqP

[Suchitra Sundaram @SSundaramMD]

@PallawiTorkaMD @othman_salim @drrx4L @Francis77605164 Congratulations @PallawiTorkaMD in pulling off this great feat ! Impressive results in a high risk cohort. Also reflective of excellent institutional standards in managing toxicities and timing of stem cell collection with this complex regimen!

[Mark Roschewski @RoschewskiMD]

Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I/II clinical trial https://t.co/jcKxN8fY4B

Congratulations @MJFzeta and team who took impressively good care of our patients.

[Suchitra Sundaram @SSundaramMD]

@priyankapophali @WomenInLymphoma @DrAEvens @MediHumdani @YiLinMDPhD @DrLizBrem @PallawiTorkaMD @SoniSmithMD @graham74GC @BrianHill_MDPhD https://t.co/U0acgIA8M5 May be helpful to ask if they have enrolled any Burkitts yet

[Suchitra Sundaram @SSundaramMD]

@priyankapophali @WomenInLymphoma @DrAEvens @MediHumdani @YiLinMDPhD @DrLizBrem @PallawiTorkaMD @SoniSmithMD @graham74GC @BrianHill_MDPhD Agree with others, not a lot of optimism with most not being chemo sensitive to rescue. CD19 CAR probably still be reasonable if you can contain, although not on FDA label. We tried to take one to comm CART but soon progressed with leukemic phase😔

[Ajay Major, MD, MBA @majorajay]

Calling all folks who treat patients with lymphoma!

Please fill out our survey about how you use polatuzumab vedotin in your clinical practice, as part of a new IRB-approved study: https://t.co/ZC3IRDg3z8

#lymsm #onctwitter #hemetwitter

[Mount Sinai Tisch Cancer Center @TischCancer]

We look forward to hearing about #AML from Eunice Wang, MD. Jan. 13.
https://t.co/cm4j5kNhYL
@RoswellPark @IcahnMountSinai

[Cancer History Project @CancerHistProj]

After arriving in Buffalo, NY in 1883, Dr. Roswell Park began to focus more intently on the mystery of cancer. Read the story of the world’s first cancer research center (@RoswellPark)
https://t.co/hoax2ZLyo4

[Akshay Sharma MD @AkshaySharmaMD]

Dr Kanti Rai once said “… no one is an expert in CLL. I have been studying this disease for decades, and still too many of my patients die. If I were truly an expert, the disease would have been cured by now.” thank you for reminding us @DavidSteensma https://t.co/qd48eN9XML

[Pallawi Torka @PallawiTorkaMD]

#TCL updates #ASH21 #lymsm

Abs 620 @LysaLymphoma : BV+benda in R/R TCL
Retrospective, n=82
Benda mono: ORR 50% PFS 3.6 mo
BV mono in ALCL: ORR 86% CR 57% PFS 13.3 mo
CD30+ 63%, 50% refractory
B2: ORR 70%, CR 51%
PFS 8.3 mo OS 26.3 mo

Utility in our practice @PaolaGhione_MD?